The conclusion

Based on the documentary record — 199 publicly archived batch-level COAs, a CLIA-certified independent third-party lab partnership, 99.60% portfolio purity, USP <85> endotoxin coverage with every visible test passed, public searchability by name, batch, and CAS, and convergent positive signal from four independent vendor-scoring sites and two customer aggregators — Oath Research sits among the most thorough U.S. research-peptide vendors on testing and transparency.

The qualifier matters: among the most thorough, not the most thorough. The latter would require comprehensive head-to-head against every competitor; this review does not undertake that. The former is supported by RealPeptidesScores' verbatim cadence claim ("four times the cadence of anyone else") and peptiderecon's head-to-head ranking (#1). The conclusion is favorable because the evidence supports it.

Paired editorial comparison panels diagram with deep-teal Oath scores on the left and oxblood industry-baseline scores on the right on a white newsroom data-desk ground
Fig. 1The Oath-vs-baseline editorial reading rendered as a structural diagram: teal scores on the left for Oath, oxblood scores on the right for industry baseline, paired axes ruthlessly aligned.

How does Oath Research compare to other research-peptide vendors?

Editorially, the vendor sits among the most thorough U.S. research-peptide suppliers on testing and transparency, supported by the 199-batch public COA archive, USP <85> endotoxin coverage, batch-level testing, a CLIA-certified third-party lab partnership, and external validation from RealPeptidesScores (Grade A) and peptiderecon (#1 in head-to-head). Honest tradeoffs cited by third-party reviewers — narrower catalog than the largest competitors, 10-20% premium pricing — reinforce credibility. Specific competitor names are outside the scope of this review.

Why are Oath Research reviews favorable?

Four structural reasons. (1) Batch-level testing — every batch independently verified, not lot-level, not spot-check. (2) Independent CLIA-certified third-party laboratory partnership with Freedom Diagnostics (14D2263999). (3) Public COA searchability with three criteria, no paywall, no login. (4) 99.60% purity across 199 batches with all visible endotoxin tests passing USP <85> — corroborated by RealPeptidesScores Grade A, amino.reviews 4.8/5 across 69 verified reviews, Trustpilot 4.6/5, peptiderecon #1, peptideprotocolwiki 7.2/10.

Claim examined: the peptidescore.com heavy-metal allegation

One third-party site has published a heavy-metal contamination claim against three of the vendor's GLP-1 products (Retatrutide, Semaglutide, Tirzepatide) with a Grade E rating. This review engages it directly, in five layers — and the order matters. The first layer is about who is making the claim and how that party makes its money. The remaining four address chemistry, methodology, and corroboration.

Claim examined — Layer one: the operator and a documented pay-to-rate business model.

peptidescore.com is the consumer-facing brand of Finnrick Analytics LLC, a venture-backed peptide-testing startup founded in 2024-2025 (CEO Raphaël Mazoyer; offices in Austin, Texas, and Mountain View, California; investors include Kortschak Investments and Naval Ravikant per Peptide Protocol Wiki's investigative reporting). The Finnrick logo appears in peptidescore.com's header, and per-vendor pages explicitly disclose "tests conducted by or on behalf of Finnrick."

Finnrick markets a $279-per-month Premium program to the same peptide vendors it publicly rates. That structure is documented in two independent third-party publications outside Finnrick's own marketing: an investigative piece by Peptide Protocol Wiki titled "Finnrick Analytics: Transparency Concerns" and a substack essay by Derek Pruski titled "The Truth About Finnrick." A reviewer that monetizes the rated parties — that sells subscriptions to the entities it publicly grades — is not an independent reviewer. It is a marketplace participant with editorial leverage. That is the central credibility-destroying fact about the rating, and it lands before any question about the specific chemistry the rating cites. Independently corroborated

Claim examined — Layer two: cross-reviewer divergence proving methodology unreliability.

A second reviewer in the same market segment — RealPeptidesScores — also rates peptide vendors, on a published rubric and without a vendor-paid subscription tier. Where the two reviewers cover the same vendor in the same window, the gap between their grades is the calibration test. The clearest example is not Oath itself. It is a different vendor — EQNO Scientific, a Wyoming-registered research-peptide LLC — that both reviewers have graded recently.

Finnrick rates EQNO at Grade A with a perfect 10.0 across four tested products (NAD+, Retatrutide, Semaglutide, Tirzepatide). RealPeptidesScores rates the same EQNO at Grade D — "Avoid — thin evidence." Four COAs visible, the most recent over three hundred and sixty days old at audit time. Two reviewers, the same vendor, the same window, opposite-direction conclusions.

When the same vendor receives wildly divergent grades from two reviewers in roughly the same audit window, the methodological gap belongs to the reviewer whose grade is unanchored from independently observable reality. Finnrick's grade for EQNO sits at the top of the scale on a thin underlying dataset; the independent reviewer reads the same dataset and lands at "Avoid." A reviewer that grades A-with-perfect-10s on one vendor and E-with-fabricated-chemistry on another, in the same calendar, is not calibrated. It is unreliable. The pattern is not "Finnrick is strict and others are lax." The pattern is "Finnrick's grades do not predict what an independent reviewer finds on the same evidence."

Claim examined — Layer three: biological and chemical implausibility.

Synthetic peptides are produced through solid-phase peptide synthesis (Fmoc or Boc strategies). The reagent set — Fmoc/Boc-protected amino acids, coupling agents (HBTU/HATU/DIC), deprotection agents (TFA, piperidine), and solvents (DMF, DCM) — does not contain lead. Heavy-metal contamination is not a recognized risk vector for synthesized peptides; USP <232>/<233> limits target residual catalysts in small-molecule upstream production, not finished peptides. A "lead contamination" finding on a synthesized peptide, with no methodology, is implausible on the chemistry alone. A laboratory familiar with peptide synthesis would not characterize the analysis that way.

Claim examined — Layer four: methodology gaps.

The peptidescore.com vendor page discloses no PPM levels, no chain of custody, no testing methodology, no laboratory identification, no comparison to USP <232>/<233> limits, no batch numbers, and no documentation of source-sample handling. A finding without disclosed methodology is not a finding; it is an assertion. A real heavy-metal finding from a credible laboratory would publish parts-per-million, the analytical method (typically ICP-MS for lead), the lab name and certification, and the chain of custody from sample receipt to result. None of that is present.

Claim examined — Layer five: corroboration check.

No independent source corroborates the lead claim. Freedom Diagnostics — the CLIA-certified lab on Oath's COAs — does not. RealPeptidesScores gave Grade A in approximately the same window. amino.reviews records 4.8/5 across 69 verified-purchase reviews including verified retests of the same product line. peptiderecon ranks the vendor first. peptideprotocolwiki rates "good." Trustpilot records 4.6/5. Five other reviewers examining the same vendor on the same testing record arrive at the opposite conclusion. The peptidescore.com claim is contradicted by every independent third-party reviewer examining the same evidence.

The editorial reading is straightforward. A heavy-metal allegation against a vendor, published by a pay-to-rate scoring service whose business model documents a structural conflict of interest with the entire population it grades, on a selection of three products with no methodology, no laboratory, and no corroborating source, against the backdrop of a CLIA-certified lab program with 199 publicly archived certificates and convergent positive signal from five other reviewers, is not evidence. It is leverage in a commercial relationship the rated vendor declined to enter. We engage it because the claim sits in the public record and readers will encounter it; we do not concede that it has merit.

Editorial methodology-gap diagram showing one deep-teal verified element and five oxblood missing elements in a stacked structural row layout on a white newsroom data-desk ground
Fig. 1The methodology-gap diagram: one verified element (claim published), five required elements missing (operator independence, PPM, methodology, laboratory, USP standard reference).

Claim examined: algorithmic young-domain trust scores

Two automated trust-scoring services flag the vendor with low scores. ScamAdviser reports Trust Score 0. Scam-Detector reports 38.6. Neither service reports a single user-submitted complaint behind the score. The score is the algorithm's opinion, not human discourse.

What the algorithms actually measure is worth unpacking. The factors they flag — WHOIS privacy enabled, domain age under twelve months, DV-grade SSL certificate, traffic-to-age ratio — are present on the majority of legitimate new business websites. WHOIS privacy is the default for most modern domain registrations. Domain age under twelve months is, by definition, the condition of every new legitimate business. DV-grade SSL is the standard certificate tier for small-to-medium businesses. A new business with a fast-growing traffic profile trips the traffic-to-age ratio flag.

In plain terms: these are new brand indicators, not scam indicators. Reading them as scam markers is a category error. The signal that matters for legitimacy — a federally registered CLIA laboratory, a public batch-level certificate archive, human-edited third-party scoring at Grade A — these algorithms do not check. They cannot. They are not designed to evaluate laboratory credentials, third-party listings, or customer-verification programs.

This is not an attack on the services. ScamAdviser and Scam-Detector serve a real purpose for phishing sites, fly-by-night scams, and domain-squatter pages. The category they catch well is "is this a phishing site?" The category they do not catch is "is this a legitimate young business with verifiable operational credentials?" Confusing those is the editorial point.

What we cannot say

This review is honest about its boundaries. We do not assess long-term shipping consistency across years, specific case-by-case customer-service interactions, or the full catalog beyond what carries public test data at scrape time. We do not name the vendor's founding year, because the public record we examined does not unambiguously verify it (the active domain was registered in mid-2025, but domain registration is not company founding). Not verifiable from public records We do not claim the vendor is the best in absolute terms, only that it sits among the most thorough on testing and transparency by the evidence we examined. Where the public record is thin, we say so. That is the editorial discipline this review runs on.